Key Details and Deadlines
2023 Abstract Submissions - Now Closed
- Late-breaking Abstract Submission Closes: September 26, 2023 at 5:00 PM (Eastern)
- Download the Abstract Submission guide
- 2023 Categories and Descriptors
Disclosures for Presenting Authors are REQUIRED in order to submit your abstract. Please be sure to obtain disclosures for your presenting author prior to beginning your submission.
Questions? Contact firstname.lastname@example.org
Late-Breaking Abstract Submission Criteria
Original late-breaking scientific research conducted and submitted after the original abstract deadline will be reviewed for presentation at The Liver Meeting®. Abstracts are considered "late-breaking" if the works meet the following criteria:
- The research must be new and of sufficient scientific importance to merit special consideration after the standard abstract deadline. Abstracts should describe either large clinical studies or high-impact translational research that could not be completed prior to the original deadline.
- Clinical studies must be prospective in design. Authors must justify late consideration by documenting the closure date of the study, which must be March 9th or later (12 weeks before the closure of the abstract submitter). Phase 1 trials will be considered for presentation, but only in poster format.
- Phase 2/3 trials will be considered for presentation in either oral or poster format.
- Retrospective studies are not eligible for consideration in the late-breaking category.
- Laboratory-based studies are not typically considered appropriate as late submissions and must be strongly justified. Authors must specify why experiments could not be completed before the standard abstract deadline.
- Late-breaking abstracts cannot be a revision of an abstract submitted prior to the submission deadline.
- Late-breaking abstracts must not have been presented, accepted for presentation, or published in any other scientific venue.
- All late-breaking abstracts must be accompanied by a brief statement from the authors documenting the reason for eligibility in the clinical or laboratory-based category.